Lodestar Supports IBM Watson Health’s Go-To-Market Strategy
Princeton, NJ, October 10, 2017 – Lodestar announced today that it has been selected to conduct go-to-market research and strategy support for IBM Watson Health. Initial work will center on the Watson for Oncology product and involve mapping the buyers journey for sophisticated decision tools for oncologists inside Integrated Delivery Network and Community Hospitals.
A second study will focus on the Watson for Genomics product and involve in-depth interviews with oncologists, molecular pathologists, and bioinformaticists involved in the gene sequencing of cancer tumors and the interpretation and patient action planning arising from such information.
Lodestar CEO Dr. Tom Nelson commented, “IBM Watson’s application of artificial intelligence to healthcare decision-making is literally the future of medicine. We are delight to be partnering with the Watson Health team in understanding how their cutting-edge solutions can most effectively be taken to market.”
Lodestar is an advisory services firm that helps clients create, manage, and utilize information and intelligence of all kinds to solve complex business problems. Our work has two goals: improve business performance and drive growth.
The firm is built around six major practice areas – marketing research and decision sciences, information management, innovation, marketing effectiveness, customer experience management, and strategy acceleration. We also offer specialized services in areas such as competitive intelligence, technology scouting, intellectual property assessment, future forecasting, performance measurement, marketing effectiveness, ROI assessment, strategic planning, sales force effectiveness, and go-to-market strategy.
Lodestar works with Fortune 1000 and SMB clients across a variety of industries, including financial services, healthcare and life sciences, media, publishing, technology, professional services, manufacturing, and the public sector.